Abstract
Botulinum toxin is the ultimate example of the core principle in toxicology that all substances are poisons, and it is only the dose that determines if a substance is therapeutic or toxic. Two forms of pharmaceutical products, onabotulinum toxin A (Botox) and rimabotulinum toxin B (Myobloc), are used as injectable therapeutic agents to induce local muscle paralysis to treat a growing variety of disorders from dystonia to bladder spasm, as well as cosmetic enhancer to flatten facial wrinkles. More botulinum-based products for these, and other, purposes are under development. As a toxin, botulinum, when ingested, is one of the most lethal on a weight per kilogram basis with a LD50 of 0.001 ug/kg [1].
Similar content being viewed by others
References
Arnon SS, Schechter R, Inglesby TV, et al. Botulism toxin as a biological weapon: medical and public health management. JAMA. 2001;285:1059–70.
Rosseto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev. 2014;12:535–49.
Sobel J, Tucker N, Sulka A, et al. Foodborne botulism in the United States, 1990–2000. Emerg Infect Dis. 2004;10:1606–11.
Anon. Centers for Disease Control and Prevention. Botulism in the United States, 1899–1996. Handbook for epidemiologists, clinicians, and laboratory workers. Atlanta: Centers for Disease Control and Prevention; 1998.
Leclair D, Pagotto F, Farber JM, et al. Comparison of DNA fingerprinting methods for use in Investigation of Type E botulism outbreaks in the Canadian Arctic. J Clin Microbiol. 2006;44:1635–44.
Horowitz BZ. Type E botulism. Clin Toxicol. 2010;48(9):880–95.
Gupta A, Sumner CJ, Castor M, et al. Adult botulism type F in the United States, 1981–2002. Neurology. 2005;65:1694–700.
Richardson WH, Frei SS, Williams SR. A case of type F botulism in Southern California. J Toxicol Clin Toxicol. 2004;42:383–7.
Sonnabend O, Sonnabend W, Heinzle R, et al. Isolation of Clostridium botulinum type G and identification of Type G botulinal toxin in humans: report of five sudden unexpected deaths. J Infect Dis. 1981;143:22–7.
Barash JR, Arnon SS. A novel strain of Clostridium botulinum that produces type B and type H botulinum toxins. J Infect Dis. 2014;209(2):183–91.
Dover N, Barash JR, Hill KK, et al. Molecular characterization of a novel botulinum neurotoxin type H gene. J Infect Dis. 2014;209(1):192–202.
Geiges ML. The history of botulism. Curr Probl Dermatol. 2002;30:77–93.
Erbguth RJ, Nauman M. Historical aspects of botulinum toxin: Justinus Kerner (1786–1862) and the “sausage poison”. Neurology. 1999;53:1850–3.
Erbguth FJ. Historical notes on botulism, Clostridium botulinum, botulinum toxin, and the idea of the therapeutic use of the toxin. Mov Disord. 2004;19 Suppl 8:S2–6.
Erbguth FJ, Naumann M. On the first systematic descriptions of botulism and botulinum toxin by Justinus Kerner (1786–1862). J Hist Neurosci. 2000;9:218–20.
Erbguth FJ. From poison to remedy: the chequered history of botulinum toxin. J Neural Transm. 2008;115:559–65.
Van Ermengem E. A new anaerobic bacillus and its relation to botulism. (English translation of original manuscript). Rev Infect Dis. 1979;1:701–19.
Dickson EC. Botulism: its occurrence in California. Calif State J Med. 1916;14:143–5.
Dembek ZF, Smith LA, Rusnak JM. Botulism: cause, effects, diagnosis, clinical and laboratory identification and treatment modalities. Disaster Med Public Health Prep. 2007;1(2):122–34.
Caya JG, Agni R, Miller JE. Clostridium botulinum and the clinical laboratorian: a detailed review, including Biologic warfare ramifications of botulinum toxin. Arch Pathol Lab Med. 2004;128:653–62.
Horowitz BZ. Botulinum toxin. Crit Care Med. 2005;21(4):825–39.
Simpson LL. Identification of the major steps in botulinum toxin action. Annu Rev Pharmacol Toxicol. 2004;44:167–93.
Ahnert-Hilger G, et al. Synaptic vesicle proteins: targets and routes for botulinum neurotoxins. In: Rummel A, Binz T, editors. Botulinum neurotoxins. Current topics in microbiology and immunology. Berlin/Heidelberg: Springer; 2013. p. 173. ISBN: 978-3-642-33569-3.
Cherington M. Clinical spectrum of botulism. Muscle Nerve. 1998;21:701–10.
Schiavo G, Santucci A, Dasgupta BR, et al. Botulinum neurotoxin serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds. FEBS Lett. 1993;335:99–103.
Horowitz BZ. History of botulism. In: Rasetti-Escargueil C, Surman-Lee S, editors. Clostridium botulinum: a spore forming organism and a challenge to food safety, Advances in food safety and food microbiology. NY: Nova Sciences Publishers; 2012.
Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review. Ann Intern Med. 1998;129:221–8.
Hughes JM, Blumenthal JR, Merson MH, et al. Clinical features of types A and B food-borne botulism. Ann Intern Med. 1981;95:442–5.
Barrett DH. Endemic food-borne botulism: clinical experience, 1973–1986 at Alaska Native Medical Center. Alaska Med. 1991;33:101–8.
Wilcox PG, Morrison NJ, Pardy RL. Recovery of the ventilatory and upper airway muscles and exercise performance after type A botulism. Chest. 1990;98:620–6.
Passaro DJ, Werner SB, McGee J, et al. Wound botulism associated with black tar heroin among injecting drug users. JAMA. 1996;279:859–63.
Bradley WG. Case 48–1980, weekly clinical-pathologic exercises. N Engl J Med. 1980;303(23):1347–55.
Sheppard YD, Middleton D, Whitfiled Y, et al. Intestinal toxemia botulism in 3 adults, Ontario, Canada, 2006–2008. Emerg Infect Dis. 2012;209(2):183–91.
McCroskey LM, Hatheway CL. Laboratory findings in four cases of adult botulism suggest colonization of the intestinal tract. J Clin Microbiol. 1988;26(5):1052–4.
Arnon SS, Schechter R, Maslanka SE, et al. Human botulism immune globulin for the treatment of infant botulism. N Engl J Med. 2006;354(5):462–71.
Pifko E, Price A, Sterner S. Infant botulism and indications for administration of the botulism immune globulin. Pediatr Emerg Care. 2014;30(2):120–4.
Long SS. Infant botulism and treatment with BIG-IV (BabyBig). Pediatr Infect Dis J. 2007;26(3):261–2.
Tsai HJ, Liang WC, Wang CH, et al. Botulism with unusual rapid progression to completer paralysis in a child. Pediatr Neonatol. 2013;3:1–4.
Brown N, Desai S. Infantile botulism: a case report and review. J Emerg Med. 2013;45(6):842–5.
Kobayashi T, Haginoya K, Morimoto T, et al. A case of infant botulism due to consumption of untreated well water. J Pediatr. 2014;164:931–3.
Harvey SM, Sturgeon J, Dassey DE. Botulism due to Clostridium baratii type F toxin. J Clin Microbiol. 2002;40(6):2260–2.
Abe Y, Negasawa T, Monma C, Oka A. Infantile botulism caused by Clostridium butyricum type E toxin. Pediatr Neurol. 2008;38(1):55–7.
Aureli P, Fenicia L, Pasolini B, et al. Two cases of type E infant botulism caused by neurotoxigenic Clostridium butyricum in Italy. J Infect Dis. 1986;154(2):207–9.
Arnon SS, Midura TF, Clay SA, et al. Infant botulism: epidemiological, clinical, and laboratory aspects. JAMA. 1977;237:1946–51.
Reddy V, Balter S, Weiss D, Layton M. Infant botulism – New York City, 2001–2001. MMWR. 2003;52:21–4.
Arnon SS, Midura TF, Damus K, et al. Honey and other environmental risk f actors for infant botulism. J Pediatr. 1979;94:331–6.
Merson MH, Dowell VR. Epidemiologic, clinical, and laboratory aspects of wound botulism. N Engl J Med. 1973;289:1005–10.
Horowitz BZ, Swensen E. Wound botulism associated with black tar heroin. JAMA. 1988;280:1479–80.
Maselli RA, Ellis W, Mandler RN, et al. Cluster of wound botulism in California: clinical, electrophysiologic and pathologic study. Muscle Nerve. 1997;20:1284–95.
Spitters C, Moran J, Kruse D, et al. Wound botulism among black tar heroin users – Washington, 2003. MMWR. 2003;52:885–6.
Werner SB, Passaro D, McGee J, et al. Wound Botulism in California, 1951–1998: recent epidemic in heroin injectors. Clin Infect Dis. 2000;31:1018–24.
Burningham MD, Walter FG, Mechem C, et al. Wound botulism. Ann Emerg Med. 1994;24:1184–7.
Offerman SR, Schaefer M, Thundiyil JG, et al. Wound botulism in injection drug users: time to antitoxin correlates with Intensive care unit length of stay. West J Emerg Med. 2009;10(4):251–6.
Middlebrook JL, Franz DR. Botulinum toxins. In: Sidell FR, Takafuji ET, Franz DR, editors. Medical aspects of chemical and biological warfare. Washington, DC: Office of the Surgeon General, Dept of the Army; 1997. p. 643–54.
Zilinskas RA. Iraq’s biological weapons: the past as future? JAMA. 1997;278:418–24.
Chertow DS, Tan ET, Maslanka SE, et al. Botulism in four adults following cosmetic injections with an unlicensed, highly concentrated botulinum preparation. JAMA. 2006;296:2476–9.
Woodruff BA, Griffin PM, McCroskey LM, et al. Clinical and laboratory comparison of botulism from toxin types A, B, and E in the United States, 1975–1988. J Infect Dis. 1992;166:1281–3.
St. Louis ME, Peck SHS, Bowering D, et al. Botulism from chopped garlic: delayed recognition of a major outbreak. Ann Intern Med. 1988;108:363–8.
Koga M, Yuki N. Hirata, Antecedent symptoms in Guillain-Barre syndrome: an important indicator for clinical and serological subgroups. Acta Neurol Scand. 2001;103:278–87.
Terranova W, Palumbo JN, Breman JG. Ocular findings in botulism type B. JAMA. 1979;241:475–7.
Ferreira JL, Eliasberg SJ, Edmonds P, et al. Comparison of the mouse bioassay and enzyme-linked immunosorbent assay procedures for the detection of type A botulinal toxin in food. J Food Prot. 2004;67:203–6.
Angulo FJ, Getz J, Taylor JP, et al. A Large outbreak of botulism: the hazardous baked potato. J Infect Dis. 1998;78:172–7.
Centers for Disease Control and Prevention (CDC). Investigational Heptavalent Botulinum Antitoxin (HBAT) to replace licensed Botulinum antitoxin AB and investigational Botulinum antitoxin E. MMWR. 2010;59(10):299.
Black RE, Gunn RA. Hypersensitivity reactions associated with botulinal antitoxin. Am J Med. 1980;69:567–70.
Hibbs RG, Weber JT, Corwin A, et al. Experience with the Use of an Investigational F(ab’)2 Heptavalent botulism immune globulin of equine origin during an outbreak of type E botulism in Egypt. Clin Infect Dis. 1996;23:337–40.
Weber JT, Hibbs RG, Darwish A, et al. A massive outbreak of type E botulism associated with traditional salted fish in Cairo. J Infect Dis. 1993;167:451–4.
Ungchusak K, Chunsuttiwat S, Braden CR, et al. The need for global planned mobilization of essential medicine: lessons from a massive Thai botulism outbreak. Bull World Health Organ. 2007;85:238–40.
Castrodale L. Botulism in Alaska: a guide for physicians and healthcare providers: 2011 update. Produced by the Department of Health and Social Services, Division of Public Health, Section of Epidemiology. Anchorage, AK. 2011.
Wilcox PG, Andolfatto G, Fairbarn MS, et al. Long-term follow-up of symptoms, pulmonary function, respiratory muscle strength, and exercise performance after botulism. Am Rev Respir Dis. 1989;139:157–63.
Metzger JR, Lewis LE. Human-derived immune globulins for the treatment of botulism. Rev Infect Dis. 1979;1:689–92.
Torii Y, Tokumaru Y, Kawaguchi S, et al. Production and Immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. Vaccine. 2002;20:2556–61.
Smith LA, Rusnak JM. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol. 2007;27:303–18.
Rusnak JM, Smith LA. Botulinum neurotoxin vaccines: past history and recent developments. Hum Vaccin. 2009;5:794–805.
Smith LA. Botulism and vaccines for its prevention. Vaccine. 2009;27:D33–9.
Centers for Disease Control and Prevention (CDC). Notice of CDC’s discontinuation of investigational pentavalent (ABCDE) botulinum toxoid vaccine for workers at risk for occupational exposure to botulinum toxins. MMWR. 2011;60(42):1454–5.
Tacket CO, Shandera WX, Mann JM, et al. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. Am J Med. 1984;76:794–8.
Gottlieb SL, Kretsinger K, Tarkhashvili N, et al. Long-term outcomes of 217 botulism cases in the Republic of Georgia. Clin Infect Dis. 2007;45:174–80.
Sobel J. Diagnosis and treatment of botulism: a century later, clinical suspicion remains the cornerstone. Clin Infect Dis. 2009;48:1674–5.
Tseng-Ong L, Mitchell WG. Infant botulism: 20 years’ experience at a single institution. J Child Neurol. 2007;22(12):1333–7.
Underwood K, Rubin S, Deakers T, Newth C. Infant botulism: a 30-year experience spanning the introduction of botulism immune globulin intravenous in the intensive care unit at Children’s Hospital Los Angeles. Pediatrics. 2007;120(6):1380–5.
Hatheway CH, Snyder JD, Seals JE, et al. Antitoxin levels in botulism patients treated with trivalent botulism antitoxin to toxin types A, B, and E. J Infect Dis. 1984;150:407–12.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Grading System for Levels of Evidence Supporting Recommendations in Critical Care Toxicology, 2nd Edition
Grading System for Levels of Evidence Supporting Recommendations in Critical Care Toxicology, 2nd Edition
-
I
Evidence obtained from at least one properly randomized controlled trial.
-
II-1
Evidence obtained from well-designed controlled trials without randomization.
-
II-2
Evidence obtained from well-designed cohort or case–control analytic studies, preferably from more than one center or research group.
-
II-3
Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled experiments (such as the results of the introduction of penicillin treatment in the 1940s) could also be regarded as this type of evidence.
-
III
Opinions of respected authorities, based on clinical experience, descriptive studies, and case reports, or reports of expert committees.
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this entry
Cite this entry
Horowitz, B.Z. (2017). Botulism. In: Brent, J., Burkhart, K., Dargan, P., Hatten, B., Megarbane, B., Palmer, R. (eds) Critical Care Toxicology. Springer, Cham. https://doi.org/10.1007/978-3-319-20790-2_126-2
Download citation
DOI: https://doi.org/10.1007/978-3-319-20790-2_126-2
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-20790-2
Online ISBN: 978-3-319-20790-2
eBook Packages: Springer Reference Biomedicine and Life SciencesReference Module Biomedical and Life Sciences